Harrow, Inc. (NASDAQ: HROW) – Q4 2025 Earnings
Harrow, Inc. (NASDAQ: HROW) – Q4 2025 Earnings
Press release and earnings call link
Section 1: Short Tear Sheeet
Overview: Harrow is a North America–focused ophthalmology (eye-care) pharmaceutical company built around acquiring, launching, and scaling prescription eye products across multiple disease areas.
Revenue drivers: A portfolio of branded ophthalmic drugs (notably VEVYE, IHEEZO, TRIESENCE) plus a meaningful “rare specialty and compounded” (custom-prepared medicines) portfolio; management is also preparing to enter the retina biosimilar market (lower-cost biologic alternatives) with BioViz.
Customers / end markets: Eye-care professionals (ophthalmologists and optometrists), with increasing emphasis on retina specialists and office-based procedures; exposure to ambulatory surgery centers (ASCs).
Positioning: Management frames Harrow as a diversified ophthalmic “platform” rather than a single-product story, aiming to scale via commercial footprint expansion and product launches.
Recent financial trajectory: Q4 revenue grew 33% YoY to $89.1M and full-year revenue grew 36% to $272.3M. Adjusted EBITDA (a non-GAAP profitability metric) rose to $24.2M in Q4 and $61.9M for 2025, with operating cash flow turning strongly positive ($43.9M vs. $(22.2)M in 2024).
Near-term themes (from management commentary): (1) scale salesforces behind core brands, (2) expand IHEEZO usage into office-based settings, (3) manage a softer 1H’26 (inventory + reimbursement changes) then accelerate in 2H’26, and (4) add new growth levers via BioViz (biosimilar) and pipeline assets (G-MELT / YOCHIL) longer-term.
Quarterly Results
Earnings Release Date: Mar. 2, 2026
Stock Price: $54.18
Market Cap: $2012.5 million
Q4 2025 sales of $89.1 million vs $66.8 million in the prior year
Q4 2025 GAAP Diluted EPS of $0.17 vs $0.24 in the prior year
Quick Takeaway
Harrow is in a scaling growth phase, focusing on commercial expansion (doubling key salesforces), new launches (BioViz/Biclovin), and evidence generation to deepen adoption, while managing near-term volatility from channel inventory and reimbursement transitions. While product momentum and guidance suggest upside, concerns center on execution risk from higher spend and the April 1 IHEEZO pass-through loss. Execution on office-based IHEEZO expansion, VEVYE new-to-brand growth, and BioViz launch traction will be critical.
Press Release vs Call Transcript Comparison
Press release = confidence + destination; call = path + speed bumps. The press release is designed to present clean momentum (record revenue, guidance, long-term targets). The call is where management implicitly asks investors to tolerate near-term noise (inventory drawdown, deductible seasonality, ASC reimbursement change) because the “real” acceleration is expected later in 2026.
The investment debate is likely to center on quality of growth. The call gives enough detail to argue both sides:
Bull view: multiple products accelerating simultaneously and expanding TAM plus new launches.
Skeptical view: some growth may be pulled forward by channel stocking, with a planned step-up in spend and reimbursement transitions that could pressure near-term results.
Investor Underappreciation Signals
✅Channel inventory vs. demand disconnect — Management expects little IHEEZO revenue in Q1 due to channel drawdown even while demand grows, and investors may misread that as a product slowdown until reported numbers re-accelerate in 2H’26.
✅IHEEZO “office-based” TAM expansion — The call quantifies ~2.5M annual office-based procedures added to TAM, which can offset the April 1 ASC reimbursement headwind faster than investors assume if adoption ramps in existing surgeon accounts.
✅Compounded-to-branded mix upgrade — Management expects compounded revenue to step down to ~$60M–$65M as volume shifts into FDA-approved branded alternatives, and investors may underestimate how much that can improve revenue quality and durability over time.
✅BioViz “low share, high profit” setup — Management is targeting only a handful of market-share points in a large retina category and leveraging an existing team, which investors may overlook because the goal sounds modest even though the profit contribution could still be meaningful.
✅Rare specialty “near-dated surprises” — The press release teases “positive surprises,” but the call ties that idea to specific near-term milestones (e.g., imminent constraint resolution and upcoming decisions/readouts), which can move sentiment quickly when disclosed.
Section 2: Supplementary Information
Positive Insights
Negative Insights
Tariff Risk
Tariffs were directly addressed: management says they do not expect meaningful tariff impact on 2026 margins, noting their prior “worst case” analysis still holds and they are “in better shape” than last year’s scenario.
No specific supply-chain shifts, renegotiations, or pricing actions were detailed—this was presented as a low-risk factor for the year.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
Q3 2025 story: Harrow is executing a multi-product ophthalmology build, but the story is still “two engines pulling hard while the rest catches up.” VEVYE and IHEEZO are growing fast and a major VEVYE coverage win (preferred PBM status starting January 2026) sets up a step-change in access and pricing mix, yet management is candid that TriEssence and rare/specialty are lagging and that a California pharmacy-license dispute is an unresolved risk.Q4 2025 story: The narrative shifts to “platform validation + engineered acceleration.” Management claims all core growth drivers are now accelerating at once, provides product-level revenue detail, and introduces a more structured 2026 guide that explicitly explains why the first half may look soft (inventory and reimbursement timing) while the second half should re-accelerate (salesforce expansion, BioViz/Biclovin launches, IHESO price improvement, and new catalysts in rare/specialty). In other words, the company moves from selling investors on “momentum + coverage upside” to selling them on “a planned, milestone-driven ramp where near-term noise is expected but the back half is the payoff.”
Year-over-year comparison (Previous Analysis)
Earlier call (Q4 2024): Harrow presents itself as a rapidly growing ophthalmic drug company proving the commercial viability of its key products. Record financial results are driven primarily by IHEEZO and VEVYE, while TRIESENCE is expected to become a larger contributor. The strategy centers on improving market access, building a strong commercial team, and expanding product adoption across ophthalmology practices. The company still frames the story as being in the early innings of product growth.
Latest call (Q4 2025): The narrative evolves to a scaled ophthalmology platform entering an acceleration phase. Management emphasizes diversification, operating leverage, and multiple growth engines simultaneously gaining traction. New strategic pillars appear, including biosimilars (BioViz) and a procedural sedation pipeline from Melt Pharmaceuticals. Financial guidance becomes more structured, and management openly discusses near-term headwinds such as reimbursement changes and inventory dynamics. The company now positions itself not just as a product company but as a dominant commercial platform in ophthalmology with multiple long-term value drivers.